NASDAQ:OPGN - OpGen Stock Price, Price Target & More

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Shares of OpGen reverse split before market open on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen (NASDAQ:OPGN) issued its quarterly earnings data on Thursday, March, 15th. The medical research company reported ($1.33) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.05. The medical research company earned $0.99 million during the quarter, compared to analyst estimates of $0.81 million. OpGen had a negative net margin of 479.38% and a negative return on equity of 1,719.89%. View OpGen's Earnings History.

2 analysts have issued 1-year target prices for OpGen's shares. Their predictions range from $9.00 to $9.00. On average, they expect OpGen's share price to reach $9.00 in the next year. View Analyst Ratings for OpGen.

Some companies that are related to OpGen include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Elekta (EKTAY), Foundation Medicine (FMI), Genomic Health (GHDX), RadNet (RDNT), Natera (NTRA), Invitae (NVTA), Enzo Biochem (ENZ), CareDx (CDNA), Veracyte (VCYT), Miragen Therapeutics (MGEN), Celcuity (CELC), Psychemedics (PMD) and Fulgent Genetics (FLGT).

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

Headlines about OPGN stock have trended somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OpGen earned a news sentiment score of 0.10 on Accern's scale. They also gave media headlines about the medical research company an impact score of 44.33 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

OpGen's stock is owned by a number of of retail and institutional investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.17%) and SABBY MANAGEMENT, LLC (5.17%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $1.92.

OpGen has a market capitalization of $10.05 million and generates $3.21 million in revenue each year. The medical research company earns $-15,410,000.00 in net income (profit) each year or ($9.78) on an earnings per share basis. OpGen employs 43 workers across the globe.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]